Celularity Inc.
GXGXW
NASDAQ Capital Market1.70
USD
+0.50
- -
CIK
0001752828
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.49
5Y
- -
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- DE United States of America
- IPO Date
- Jul 15, 2019
- CIK
- 0001752828
- Website
- celularity.com
- Similar Companies
- Business
- Celularity Inc. (Nasdaq: CELU; warrants: GXGXW) develops, manufactures and commercializes off-the-shelf allogeneic placental-derived cell therapies and advanced biomaterial products targeting aging-related degenerative diseases, cancer, immune disorders, infectious diseases and wounds; core offerings include unmodified and genetically modified natural killer (NK) cells such as CYNK-001 for acute myeloid leukemia and multiple myeloma, CAR T-cells, mesenchymal-like adherent stromal cells (MLASCs or ASCs), and commercial biomaterials comprising single-layer and tri-layer decellularized amniotic membrane allografts (Biovance and Biovance 3L), flowable human connective tissue matrix (Interfyl), CentaFlex and recently acquired Rebound therapeutic putty; the company operates through Cell Therapy, Degenerative Disease and BioBanking segments, with bio-banking generating the majority of revenue, and serves clinicians, hospitals and surgical centers focused on ophthalmology, wound care, orthopedics and vascular applications. Founded in 2017 as a spin-out from Anthrogenesis (established 1998) and headquartered at 170 Park Avenue in Florham Park, New Jersey, Celularity leverages its proprietary IMPACT platform and a 150,000 square foot GMP-capable manufacturing facility to process postpartum placentas from consented donors into scalable therapies and biomaterials. Recent developments include a major balance sheet restructuring retiring $41.6 million in senior secured debt; a strategic partnership with DefEYE Inc. featuring an in-kind investment in its $12 million Series Seed round, exclusive sublicense and pricing for ophthalmic biologics (Biovance, Biovance 3L, Interfyl, CentaFlex), and designation as exclusive contract manufacturer with board representation; acquisition of Rebound product from Sequence LifeScience to expand the biomaterial portfolio; partnerships with Fountain Life for stem cell therapies under new Florida law and a clinical-stage cell therapy company; peer-reviewed Phase 2 trial publication validating PDA-002 cells for diabetic foot ulcers; over sevenfold net product sales growth through Q3 2024 versus prior year with full-year 2024 guidance raised to reflect $44.4 million through October; FDA Tissue Reference Group recommendations for Natalin and Acelagraft wound care products; and filing of Q1/Q2 2025 10-Q reports confirming Nasdaq compliance.